New Cancer Therapy Could Give Hope To 'Incurable' Patients
A new experimental treatment has achieved what chemotherapy and bone marrow transplants have failed to do: put chronic, relapsing blood cancers into remission. What's more, it uses the body's own natural defense system to attack these cancerous growths. The treatment involves T cells, a type of immune cell that works as your body's own personal S.W.A.T. team to detect, surround, and destroy foreign invaders like bacteria or viruses. Historically, cancerous cells have grown too fast for T cells to mount an effective defense, and they can also trick T cells into thinking that they’re a healthy part of the body as opposed to a cancerous growth that needs to be stopped. But in experimental treatments at the Fred Hutchinson Cancer Research Center in Seattle, initial evidence shows Dr. Stanley Riddell has successfully trained these T cells to better recognize and eliminate cancer cells in a short time span, allowing cancer to go into remission. Specifically, he extracted a person's T cells in order to prime them to recognize the type of cancer that is affecting the patient, allowing these primed T cells to attack the growth while sparing healthy cells and tissue. The results Riddell's preliminary findings on the success of T cell therapy to cure previously terminal cases of cancer made a stir at an annual meeting of the American Association for the Advancement of Science in Washington, D.C. on Sunday because of his eye-popping results: 93 perc...
ConclusionsFOSL1 is an independent prognostic biomarker of GC. Detecting FOSL1 expression could help stratify GC patients with high-risk and guide the precious treatment.
In this study, we aimed to investigate the role of IL-6/Stat3 signaling pathway in human endometrial cancer cells invasion and migration. We demonstrated that Stat3 is activated in endometrial cancer cell lines. To investigate the role of Stat3 in endometrial cancer invasive capacity, we used Stat3 inhibitor Stattic and found that Stattic significantly inhibited the migration and invasion of endometrial cancer cells elevated by IL-6. Furthermore, we showed that Stat3 inhibitor significantly decreased the expression of MMP2 enhanced by IL-6, indicating that IL-6 promoted endometrial cancer invasion and migration by Stat3-in...
Publication date: Available online 19 March 2019Source: Pathology - Research and PracticeAuthor(s): Xiaobo He, Ying ShuAbstractIncreasing evidence has shown that dysregulation of mircoRNA (miRNA) is linked to the development and progression of human cancer, including gastric cancer (GC). In the current study, by analysing the GEO database (GSE78091), we found that miR-660 was significantly downregulated in GC. Consistently, quantitative real-time PCR (qRT-PCR) results showed that miR-660 was dramatically decreased in GC tissues and cell lines. Importantly, low miR-660 expression was closely related to larger tumor size (P&...
ConclusionsThe results pointed out that the high expression of miR-106b-5p serves as an independent factor for predicting the worse prognosis of RCC patients.
In conclusion, clinical presentation at time of diagnosis of brain metastases consistently includes neurologic signs and symptoms with persistent headache being the most common. Endometrial cancer patients that present with new neurologic complaints or exam findings should be evaluated for brain metastases.
We describe a case of an 80-year-old woman with ovarian metastasis of MCC six years after excision of a cutaneous MCC on the cheek.DiscussionTo our knowledge only three cases with ovarian metastasis of MCC have been described so far. Our case is the second with distant metastasis to the ovary spreading from a primary tumor in the skin of the head, in the other two cases the primary tumor was in the inguinal skin.ConculsionMCC is a highly aggressive cutaneous and mucosal malignancy with frequent recurrence, lymph node and distant metastases. There is no clear consensus how to treat metastatic disease.
In states that legalized medical marijuana, there was a 4.8 percent decrease in reported pain for conditions that qualified for pot treatment (cancer, arthritis, glaucoma and pain), compared to states without medical marijuana.
A new study from the UC San Diego School of Medicine found that pancreatic cancer patients live longer when they have low levels of enzxyme PHLPP1 and high levels of enzyme PKC.
The U.S. Food and Drug Administration on Wednesday said it will temporarily allow certain manufacturers to sell blood pressure medications containing specified levels of a probable cancer-causing impurity in order to maintain adequate supplies of the drug.
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review ’s (ICER) framework as the basis for accessing a medicine, an estimated 42 to 99 percent of prescriptions to treat serious, complex conditions like cancer and multiple sclerosis may not be covered. This shows the dangerous effects using ICER’s value framework could have for some of the most vuln erable patients.
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Therapy | Chemotherapy | Children | Chronic Leukemia | Chronic Lymphocytic Leukemia | Colon Cancer | Colorectal Cancer | Environmental Health | Health | Hodgkin's Disease | Hospitals | Immunotherapy | Learning | Leukemia | Lung Cancer | Lung Transplant | Lymphoma | Non-Hodgkin's Lymphoma | Science | Study | Transplant Surgery | Transplants | Universities & Medical Training | Websites